规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
1g |
|
||
Other Sizes |
|
靶点 |
BTK (Bruton's tyrosine kinase), non-covalent inhibitor
|
---|---|
体外研究 (In Vitro) |
Pirtobrutinib(LOXO-305)是下一代布鲁顿酪氨酸激酶(BTK)抑制剂,具有高度选择性、非共价性,并与WT BTK和几个BTK C481取代突变表现出强平衡结合。它还有效地抑制BTK C481S、T和R突变的细胞活性。[2]
|
体内研究 (In Vivo) |
吡妥布替尼在体内显著抑制人淋巴瘤异种移植物的肿瘤生长。[3]
|
酶活实验 |
在HotSpot激酶测定(反应生物学,Malvern,PA)中,通过监测[33P]-三磷酸腺苷(ATP)中[33P]-PO4掺入聚谷氨酸-酪氨酸(poly-EY)肽底物来测定Pirtobrutinib对BTK、BTK C481S和选定的非BTK激酶的活性。25使用标准曲线拟合方法分析数据。使用HotSpot激酶测定和Km-ATP浓度测试了Pirtobrutinib(1μM)对371种人类激酶的激酶活性抑制。使用HotSpot激酶测定法在10μM ATP的浓度下测试Pirtobrutinib、ibrutinib,zanubrutinib和acalabrutinib(100 nM)。计算每种酶的对照活性百分比。[3]
|
细胞实验 |
在加入原钒酸盐之前,用LOXO-305、伊布替尼或阿克拉布替尼处理瞬时表达WT BTK和BTK C481取代突变的HEK293T细胞系30分钟。在2小时的孵育期后,裂解细胞,并使用MesoScale(C481R)或免疫印迹(BTK-WT、C481S和C481T)鉴定总BTK和磷酸化的Y223-BTK。使用GraphPad Prism,对频带和MSD信号进行量化,并计算IC50值。
|
动物实验 |
OCI-Ly10 cells were implanted subcutaneously into male nonobese diabetic/severe combined immunodeficiency mice and tumors were allowed to grow to a volume of between ∼150 and 200 mm3. Mice were randomized by tumor size across dose groups and dosed orally twice-daily (BID) with 10 or 50 mg/kg pirtobrutinib (12 mice per group) or vehicle (11 mice per group) for 28 days. Tumor volumes were measured thrice weekly during the study and for an additional 35 days after dosing (Axis Bioservices, Coleraine, United Kingdom). In the TMD8 study, cells were injected subcutaneously into Balb/c SCID mice and allowed to grow for 19 days until a mean tumor volume of 400 mm3 was reached. Mice were randomized by tumor size across dose groups and orally dosed BID with 15 or 30 mg/kg pirtobrutinib (10 mice per group) for 18 days or vehicle (10 mice per group) for 14 days. Tumor volumes were measured thrice weekly. REC-1 cells were injected subcutaneously into female athymic nude mice and allowed to grow for 18 days when a mean tumor volume of 150 mm3 was reached. Mice were randomized by tumor volume across dose groups and orally dosed BID with pirtobrutinib at 10, 30, or 50 mg/kg (6 mice per group) or vehicle (10 mice per group) for 21 days. Tumor volumes were measured twice weekly. TMD8 cells expressing BTK C481S were injected into female Balb/c SCID mice and allowed to grow for 12 days when a mean tumor volume of 150 mm3 was reached. Mice were randomized by tumor size and orally dosed BID with pirtobrutinib at 3, 10, and 30 mg/kg (10 mice per group) or vehicle (14 mice per group) for 14 days. Tumor volumes were measured 2 or 3 times per week. Animal procedures for the OCI-Ly10 xenograft tumor studies were performed under the guidance of the United Kingdom Animal (Scientific Procedures) Act 1986. Mice used in the TMD8 and TMD8 BTK C481S studies were treated in accordance with guidelines by the Association for Assessment and Accreditation of Laboratory Animal Care International, and protocols were authorized by the French Ministry of Education, Advanced Studies and Research. All procedures used in the REC-1 xenograft study were compliant with the United States Department of Agriculture’s Animal Welfare Act (9 CFR Parts 1, 2, and 3) and the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, The National Academies Press, Washington, DC).[3]
|
参考文献 |
[1]. Blood (2019) 134 (Supplement_1): 478.
[2]. Blood (2019) 134 (Supplement_1): 4644. [3]. Blood . 2023 Jul 6;142(1):62-72. [4]. J Clin Oncol. 2015; 35:1437-1443. [5]. Haematologica. 2018; 103(5):874-879. |
相关CAS号 |
|
|
---|---|---|
外观&性状 |
Typically exists as solid at room temperature
|
|
化学名 |
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
|
|||
---|---|---|---|---|
溶解度 (体内实验) |
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。 注射用配方 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Inhibition of A2AR-mediated cAMP accumulation. Inhibition of the CGS21680-mediated cAMP accumulation. A SCH442416 and PBF509 concentration-response inhibition curve of CGS21260-mediated cAMP was assessed in HEK-293 cells permanently expressing the A2ARSNAP.Front Pharmacol.2018 Oct 19;9:1200. th> |
---|
PBF509 blocks A2AR-mediated whole cell label-free responses.Front Pharmacol.2018 Oct 19;9:1200. td> |
PBF509 reverses haloperidol-induced catalepsy. Rats were pretreated with haloperidol (1.0 mg/kg, s.c.) and 1 h later the selected cataleptic animals were orally administered with either vehicle or PBF509 (3, 10, and 30 mg/kg, p.o.).Front Pharmacol.2018 Oct 19;9:1200. td> |
PBF509 attenuates pilocarpine-induced tremulous jaw movements.Effect of different doses of SCH442416 and PBF509 on pilocarpine-induced tremulous jaw movements. The number of jaw movements were recorded during 1 h in rats orally administered with vehicle (Veh), SCH442416 or PBF509 (0.3–7.5 mg/kg) before (20 min) pilocarpine administration (1 mg/kg, i.p.).Front Pharmacol.2018 Oct 19;9:1200. th> |
---|
Immunoreactivity of A2AR in the striatum of 6-OHDA-lesioned rats.Front Pharmacol.2018 Oct 19;9:1200. td> |
PBF509-mediated potentiation ofl-DOPA-induced contralateral rotations in 6-OHDA-lesioned rats. The number of contralateral rotations in 6-OHDA-lesioned rats orally administered with vehicle (Veh) or SCH420814 and PBF509 (0.3 and 3 mg/kg) in the absence or presence ofl-DOPA (4 mg/kg) was monitored during a 2 h period.Front Pharmacol.2018 Oct 19;9:1200. td> |